Alpha Teknova, Inc. (TKNO) FY2025 10-K Annual Report

Filed: Mar 2, 2026
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR

Alpha Teknova, Inc. (TKNO) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Mar 2, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.

Alpha Teknova, Inc. FY2025 10-K Analysis

Business Overview

  • Core business model: Custom manufacturing of critical reagents for life sciences, supporting research to commercialization stages
  • New emphasis on scaling operations with investment in a new warehouse and distribution facility to improve capacity and efficiency
  • Strategic shift: Growth focus through targeted marketing, strategic partnerships, and expanded sales efforts to increase brand awareness and market presence
  • Revenue $40.5M in 2025, up $2.8M (7.4%) from 2024; operating loss narrowed to $17.0M from $26.1M in prior year
  • Entered $28.245M amended credit facility in March 2025, including $23.245M term loan and $5M working capital, with revenue and cash covenants

Risk Factors

  • Regulatory risk: compliance with Second Amended and Restated Credit Agreement net revenue covenant of $39.0M for 2025, minimum cash requirement $8.0M
  • Macroeconomic exposure: 94.4% of revenue from U.S. customers, limited international diversification with only $2.3M (5.6%) sales outside U.S. in 2025
  • Operational risk: reliance on manufacturing efficiency gains to improve gross margin to 33.2% in 2025 from 26.5% adjusted in 2024
  • Competitive risk: reduced R&D spend by 20.4% to $2.2M in 2025 vs $2.8M in 2024, potentially impacting innovation versus peers
  • Financial risk: $13.2M outstanding term loan with related $1.1M exit fee and total accumulated deficit of $135.8M as of December 31, 2025

Alpha Teknova, Inc. FY2025 Key Financial Metrics
XBRL

Revenue

$41M

+7.4% YoY

Net Income

-$17M

+35.5% YoY

Gross Margin

33.2%

+1401bp YoY

Operating Margin

-41.9%

+2737bp YoY

Net Margin

-42.6%

+2826bp YoY

ROE

-25.1%

+737bp YoY

Total Assets

$104M

-12.8% YoY

EPS (Diluted)

$-0.32

+43.9% YoY

Operating Cash Flow

-$9M

+30.2% YoY

Source: XBRL data from Alpha Teknova, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on Alpha Teknova, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.